Skip to main content
. 2021 Mar 10;60(11):5185–5193. doi: 10.1093/rheumatology/keab217

Fig. 2.


Fig. 2

Forest plots depicting hazard ratio (HR) with corresponding 95% CI of immunosuppressant/biologic use with lymphopenia (A) and neutropenia (B)

HR was adjusted for prednisolone use, anti-malarial use and SLEDAI-2K score. BEL: belimumab; CyA: ciclosporin; MPA: mycophenolic acid; RTX: rituximab; TAC: tacrolimus.